Source: Cardiovascular Business

Hydroxychloroquine is associated with reducing ICU admissions among hospitalized COVID-19 patients, according to new findings published in the International Journal of Infectious Diseases. Chloroquine, however, was not found to have such an effect.

Hydroxychloroquine and chloroquine are antimalarial drugs that have been at the center of dozens of controversies and debates since the beginning of the COVID-19 pandemic. Early evidence suggested one, or even both, of the drugs may be a game-changer in the treatment of COVID-19. However, details related to poor cardiovascular outcomes such as arrhythmias—and some other concerning findings—led many medical professionals to urge extreme caution.

This latest study included data from more than 1,000 adult COVID-19 patients who received treatment at one of 14 hospitals in the Netherlands from Feb. 28 to April 1.   

“Based on the available evidence present at the start of the outbreak, a Dutch treatment guideline was developed,” wrote first author A.J.J. Lammers, MD, PhD, of Isla Hospital in Zwolle, the Netherlands, and colleagues. “Off-label use of both hydroxychloroquine and chloroquine was given as a treatment option; however, the guidelines did not endorse either treatment in particular. Consequently, hospitals decided independently on a treatment protocol with either hydroxychloroquine or chloroquine, or to give no treatment. This policy created a unique situation for comparing the efficacy of hydroxychloroquine and chloroquine with no treatment in hospitalized non-ICU patients with a reduction of potential bias by indication.”

Overall, the study revealed that the medications were not related to any significant changes to patient mortality. Hydroxychloroquine, however, was associated with a 53% reduction of being transferred to the ICU. Patients treated with chloroquine did not experience the same effect.

“This finding suggests that starting early treatment with hydroxychloroquine (within one day of admission) on the regular COVID-ward might prevent progression to critical respiratory illness,” the authors wrote. “This is consistent with the suggestion that hydroxychloroquine treatment reduces the risk of disease progression more effectively earlier in the course of the disease. This holds true for many other viral infections such as influenza and herpes simplex, where treatment must be initiated soon after onset of symptoms in order to confer benefit. However, treatment with hydroxychloroquine before onset of symptoms did not prevent COVID-19, as was demonstrated in a randomized controlled trial investigating post-exposure use of hydroxychloroquine.”







Related:

Choose Truth and Choose Life

How hydroxychloroquine works at the cellular level

C19study.com update: Now 88 international studies (51 peer reviewed) show positive hydroxychloroquine treatment outcomes

Belgium Study: Low-dose Hydroxychloroquine Therapy and Mortality (Lowered) in Hospitalized Patients with COVID-19: A Nationwide Observational Study of 8075 Participants

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

Trouble in Paradise Surrounding the use of Ivermectin

In nations around the world tension mounts between physicians and caregivers seeking to prescribe what they professionally deem as safe doses of ivermectin, as an off-label treatment for COVID-19 and national health authorities, which for the most part have all taken a hostile and oppositional position against the use of the drug.

Read More »

How Ivermectin became a Target for the ‘Fraud Detectives.’

And why is ivermectin being so negatively targeted by Big Tech and Big Media? One could argue conflict of interest plays a major role, given how intertwined they are with Big Pharma and the far-reaching grasp of the BMGF. A cheap and effective early treatment for Covid-19, like ivermectin, can be seen as a significant threat to the financial interests of those involved with Covid vaccines and expensive anti-viral drugs.

Read More »

Canada: Alberta Failing on COVID-19 Vaccines and Treatment

Numerous studies and clinical observation of thousands of patients has indicated that Ivermectin is highly effective in this regard. Even low dose studies that were designed to reach the conclusion that ivermectin was not effective found a signal that indicated that Ivermectin effectively interacted with the COVID virus molecule to prevent or lessen replication of the virus.”

Read More »